Amberstone Biosciences: Funding, Investors & Team (Sep 2026)
Amberstone Biosciences discovers novel immunotherapies through innovative technologies and creative partnerships. Amberstone's focus is difficult targets requiring a unique mode-of-action and/or particular functional property, which are otherwise challenging for traditional approaches. These conventional limitations are overcome via a two-pronged approach. First, we have demonstrated success with our microfluidics-powered AmberFlow drug-discovery platform. Second, our team of experts has keen insights in immuno-oncology and ample experience with single-cell assay biology.
Amberstone Biosciences has raised $12.0M across 1 funding round on record, the most recent a Series A of $12.0M announced in Jan 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Amberstone Biosciences Company Profile and Key Stats
Latest funding round on record: Jan 2022.
Amberstone Biosciences Funding Rounds
Amberstone Biosciences Founders and Leadership Team
Contact details for the Amberstone Biosciences team: 1 of 1 has an email address on file.
Start 14-day free trial →Amberstone Biosciences Funding Compared to Other Biotechnology Startups
Amberstone Biosciences' latest round of $12.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Amberstone Biosciences in Biotechnology and Laguna Hills
Companies Similar to Amberstone Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Amberstone Biosciences Funding FAQs
What does Amberstone Biosciences do?
Amberstone Biosciences discovers novel immunotherapies through innovative technologies and creative partnerships. Amberstone's focus is difficult targets requiring a unique mode-of-action and/or particular functional property, which are otherwise challenging for traditional approaches. These conventional limitations are overcome via a two-pronged approach. First, we have demonstrated success with our microfluidics-powered AmberFlow drug-discovery platform. Second, our team of experts has keen insights in immuno-oncology and ample experience with single-cell assay biology.
How much funding has Amberstone Biosciences raised?
Amberstone Biosciences has raised $12.0M across 1 round on record. The most recent is a Series A of $12.0M announced in Jan 2022.
When did Amberstone Biosciences last raise funding?
Amberstone Biosciences' most recent funding round on record is a Series A of $12.0M, announced in Jan 2022.
Who is the CEO of Amberstone Biosciences?
George Wu is listed as CEO at Amberstone Biosciences.
Where is Amberstone Biosciences headquartered?
Amberstone Biosciences is based in Laguna Hills, California, United States.
How many employees does Amberstone Biosciences have?
Amberstone Biosciences is in the 11-50 employee band.
How does Amberstone Biosciences' funding compare to other Biotechnology startups?
Amberstone Biosciences' latest round of $12.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Amberstone Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Amberstone Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.